Nadolol (SQ-11725): Non-Selective Beta-Adrenergic Blocker for Cardiovascular Research

Executive Summary: Nadolol (SQ-11725) is a non-selective, orally active beta-adrenergic receptor blocker with a molecular weight of 309.40 g/mol and chemical formula C₁₇H₂₇NO₄ (APExBIO, BA5097). It acts as a substrate of the organic anion transporting polypeptide 1A2 (OATP1A2), influencing its tissue distribution and pharmacokinetics (Sun et al., 2025). Nadolol competitively inhibits beta-adrenergic receptors, which lowers heart rate and myocardial contractility, making it a reference compound in hypertension and angina pectoris research. Its physicochemical stability requires storage at -20°C, and solution use is recommended promptly after preparation to maintain efficacy. Nadolol is intended exclusively for scientific research and is distributed by APExBIO under SKU BA5097 (link).

Biological Rationale

Nadolol is a non-selective beta-adrenergic receptor antagonist (beta-blocker) that inhibits both β₁- and β₂-adrenergic receptors. This action interrupts the beta-adrenergic signaling pathway, a key regulator of cardiovascular function. Beta-adrenergic stimulation increases heart rate, myocardial contractility, and systemic vascular resistance. Inhibiting these receptors reduces cardiac workload and oxygen consumption, which is central to experimental models of hypertension, angina pectoris, and vascular headaches (see overview). Nadolol's non-selectivity is advantageous in preclinical studies requiring broad beta-adrenergic blockade. Its OATP1A2 substrate status also allows for controlled pharmacokinetic and transporter interaction studies relevant to cardiovascular disease modeling (Sun et al., 2025).

Mechanism of Action of Nadolol (SQ-11725)

Nadolol (SQ-11725) binds competitively to beta-adrenergic receptors, preventing endogenous catecholamines (e.g., epinephrine, norepinephrine) from activating these G protein-coupled receptors. This leads to:

• Decreased heart rate (negative chronotropic effect)
• Reduced myocardial contractility (negative inotropic effect)
• Lowered systemic blood pressure (antihypertensive action)

Nadolol is orally active and demonstrates high bioavailability in animal models. As a substrate for OATP1A2, its cellular uptake and tissue distribution can be modulated by transporter expression, a key consideration in pharmacokinetic studies (Sun et al., 2025). The product’s solid form is stable for long-term storage at -20°C, while solutions must be used promptly to avoid degradation (APExBIO).

Evidence & Benchmarks

• Nadolol produces a dose-dependent reduction in systolic and diastolic blood pressure in rodent hypertension models (see Table 2, internal review).
• As an OATP1A2 substrate, Nadolol’s liver and plasma distribution is affected by transporter expression levels, enabling studies of pharmacokinetic variability (Sun et al., 2025).
• Nadolol demonstrates reproducible blockade of beta-adrenergic signaling in cell-based and in vivo models, supporting its adoption as a control agent in cardiovascular research (internal protocol).
• It remains stable at -20°C for at least 24 months in its solid form; solutions should be prepared fresh for each experiment (APExBIO).
• Long-term dosing regimens in animal models have not indicated significant off-target toxicity at standard experimental concentrations (1–10 mg/kg) (mechanistic analysis).

Applications, Limits & Misconceptions

Nadolol is used in a range of cardiovascular research models:

• Hypertension research: Validated as a standard beta-blocker to lower blood pressure in murine and rat models.
• Angina pectoris studies: Used to modulate myocardial oxygen demand and induce controlled ischemia.
• Vascular headache research: Applied in protocols modeling the autonomic contribution to migraine and vascular headaches.
• Pharmacokinetics and transporter studies: OATP1A2 substrate status enables experiments on drug-drug interactions and transporter-mediated tissue distribution.

This article extends prior reviews by integrating the latest data on OATP1A2-mediated pharmacokinetics and clarifying Nadolol’s strategic value in modeling transporter-dependent variability (link). For a focused protocol perspective, see our troubleshooting guide (link), which this article augments by emphasizing transporter interactions and experimental reproducibility.

Common Pitfalls or Misconceptions

• Nadolol is not cardioselective: It blocks both β₁ and β₂ receptors, so it cannot be used to differentiate cardiac versus pulmonary beta-adrenergic effects.
• Not suitable for diagnostic or therapeutic human use: The product is strictly for laboratory research (see APExBIO guidance).
• Solution instability: Prepared solutions degrade rapidly; use immediately for reliable results.
• Transporter expression can confound results: OATP1A2 levels may alter pharmacokinetics; always control for transporter status in comparative studies (Sun et al., 2025).
• Not a model for metabolic dysfunction: While transporter biology overlaps, Nadolol is not validated for MASLD/MASH models; see Sun et al., 2025 for MASLD-specific transporter studies.

Workflow Integration & Parameters

Handling and Storage: Store Nadolol (SQ-11725) at -20°C (solid) for up to 24 months. Prepare solutions freshly and use immediately; avoid long-term solution storage (product page).

Dosing: Typical in vivo dosing ranges from 1–10 mg/kg in rodents, adjusted for model and endpoint. For cell-based assays, 1–100 μM is common, but optimization is advised based on assay sensitivity.

Shipping: Ships with Blue Ice for small molecules. For nucleotides, Dry Ice is used (see shipping policy).

Experimental Readouts: Monitor heart rate, blood pressure, and, where relevant, tissue-specific beta-adrenergic signaling. For pharmacokinetic studies, measure plasma and tissue concentrations using validated LC-MS/MS protocols (Sun et al., 2025).

Conclusion & Outlook

Nadolol (SQ-11725) from APExBIO is a validated, non-selective beta-adrenergic receptor antagonist optimized for cardiovascular research. Its OATP1A2 substrate profile enables robust pharmacokinetic and transporter interaction experiments, expanding its utility beyond classical beta-blockade. Rigorous storage, handling, and experimental design are essential to maximize reproducibility. Future work will further clarify Nadolol’s role in emerging cardiovascular disease models and transporter-focused pharmacology (advanced research).